Stay updated with breaking news from Parkinson Disease Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In science there is a term called “ground truth,” the baseline from which data is judged for accuracy. For William & Mary student Ken Koltermann, the term may better be described as “boots-on-the-ground truth.”
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α -synuclein levels in vitro and in vivo BETHESDA, Md., May 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using super-computational methods to target allosteric binding sites and guide enzymes back to their proper shape, today announced new pr...